Glycomine is a private clinical-stage biopharmaceutical company based in San Carlos, United States. The company is developing a first-in-class substrate replacement therapy for a rare pediatric neurological disorder, PMM2-CDG (congenital disorder of glycosylation). The program has demonstrated meaningful and observable clinical improvement in its Phase 2a study.
PMM2-CDG (congenital disorder of glycosylation)
CTI LSF III
Lead
Director
July 4, 2024
Active
Series C
Glycomine has a substrate replacement therapy that directly bypass the mutated enzyme in patients with PMM2-CDG; it is not only a first-in-class treatment but also the only disease modifying treatment
April 16, 2025
